Overview
Emulate provides Organ-on-a-Chip technology, including the Human Emulation System and AVA Emulation System, to model human organ functions like liver, kidney, and intestine for drug development and toxicology testing. These microfluidic platforms replicate human tissue responses more accurately than animal models, reducing R&D costs and translational failures. The company serves pharmaceutical, academic, and government researchers with validated chips for applications in cancer, immunology, and infectious diseases.
Frequently asked questions
- What Organ-Chip models does Emulate offer?
- Emulate offers Liver-Chip, Colon Intestine-Chip, Duodenum Intestine-Chip, Kidney-Chip, and consumables like Chip-S1 (stretchable), Chip-R1 (rigid for ADME/toxicology), and Chip-A1 (accessible for 3D tissue modeling).
- Is Emulate's technology validated for regulatory use?
- Emulate's Organ-Chips are supported by over 100 peer-reviewed papers, FDA fast-tracking, and collaborations with pharma giants like Pfizer and J&J; liver chips detect drug toxicity early, with NASA validation in microgravity.
- What geographies does Emulate serve?
- Emulate operates globally, serving pharmaceutical companies, academia, government, and industries in the US and internationally, with partnerships including Pfizer, J&J, and research in cancer, Alzheimer's, and rare diseases.